My issue with him is the lack of communication. Biotech stocks move up and down drastically in the clinical stage. He didn’t do what he said he was going to do
Good post Letitride. Although I can sympathize with people's frustration I think he's probably doing all that he can given our position in this brand new industry. Let's wait to see what he has to say.